New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Amgen Inc.

AMGN

Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.

Revenue
+8.45%
EPS
+19.4%
Free cash flow
−14.0%
Total debt
−1.06%

Quarter to September 2026, against a year earlier

439.53 0.73 +0.17%
Market cap
$237.4B
P/E
25.2×
Fwd P/E FY26e
24.0×
Dividend yield
2.84%
F-score
7/9
ROIC
14.3%
Net debt / EBITDA
2.9×
Payout ratio
0.7×

Amgen Inc. (AMGN) EV/FCF

Alert me on EV/FCF

As of Nov 19, 2026, Amgen Inc. (AMGN) trades at a EV/FCF of 30.4×. Over the past ten years it has ranged from 10.7× (September 2015) to 46.5× (September 2024); the current reading is higher than 91% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 28.9× 53.05%
FY2024 18.9× (38.54%)
FY2023 30.7× 50.57%
FY2022 20.4× 5.64%
FY2021 19.3× 16.27%
FY2020 16.6× (19.37%)
FY2019 20.6× 56.47%
FY2018 13.2× 7.85%
FY2017 12.2× 2.60%
FY2016 11.9× (12.27%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 29.4× 19.87%
Jun 2026 24.5× (14.93%)
Mar 2026 28.8× (0.28%)
Dec 2025 28.9× 62.95%
43 more quarters

Against its own ten years

Low 10.7× High 46.5×
Ten-year median 17.6×
Current reading's percentile 91

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on AMGN